Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

March 31, 2027

Conditions

Multiple Myeloma

Interventions

DRUG

Lenalidomide

Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone

DRUG

Lenalidomide 25 MG Oral Capsule

Oral lenalidomide for active control

Trial Locations (2)

ACTIVE_NOT_RECRUITING

Regional Oncology Center, Wilson

RECRUITING

Gabrail Cancer & Research Center, Canton

All Listed Sponsors

lead

Starton Therapeutics, Inc

INDUSTRY